Clinical Trials Logo

Leukemia, Myeloid, Chronic clinical trials

View clinical trials related to Leukemia, Myeloid, Chronic.

Filter by:

NCT ID: NCT00298987 Completed - Clinical trials for Leukemia, Myeloid, Chronic

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.

NCT ID: NCT00264160 Completed - Clinical trials for Leukemia, Myeloid, Chronic

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

This open-label, multicenter trial will evaluate the efficacy and safety of treatment with AMN107 in chronic myelogenous leukemia (CML) patients that are resistant and/or intolerant to imatinib mesylate therapy.

NCT ID: NCT00246662 Completed - Clinical trials for Myelodysplastic Syndromes

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Start date: November 14, 2005
Phase: Phase 1
Study type: Interventional

This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activity.

NCT ID: NCT00186342 Completed - Leukemia Clinical Trials

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

Start date: September 1992
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).

NCT ID: NCT00176930 Terminated - Multiple Myeloma Clinical Trials

Stem Cell Transplant for Hematological Malignancy

Start date: October 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.

NCT ID: NCT00167180 Terminated - Multiple Myeloma Clinical Trials

Post Transplant Donor Lymphocyte Infusion

Start date: January 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.

NCT ID: NCT00167167 Completed - AML Clinical Trials

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

Start date: December 1995
Phase: N/A
Study type: Interventional

In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.

NCT ID: NCT00067002 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Randomized Double Cord Blood Transplant Study

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.

NCT ID: NCT00058747 Terminated - Clinical trials for Leukemia, Myeloid, Chronic

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢

Start date: March 2003
Phase: Phase 2
Study type: Interventional

This is a Phase II, exploratory, open-label study of the investigational product AG-858, in patients who are cytogenetically positive after treatment with Gleevec. The trial will consist of three independent Phase II evaluations of patient groups according to their cytogenetic status as defined in the eligibility criteria (Eligibility Criteria 4a, 4b, and 4c).

NCT ID: NCT00050531 Completed - Clinical trials for Leukemia, Myeloid, Chronic

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Start date: April 2003
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating CML in chronic phase than therapy with imatinib mesylate alone.